Repurposing Niclosamide for COVID-19

By |2022-09-26T10:19:19-07:00September 26th, 2022|

Niclosamide, an FDA-approved oral anthelmintic drug, has broad biological activity including anticancer, antibacterial, and antiviral properties. Niclosamide has also been identified as a potent inhibitor of SARS-CoV-2 infection in vitro, generating interest in its use for the treatment or prevention of COVID-19. Unfortunately, there are several potential issues with using niclosamide for COVID-19, including low [...]

A Phase 2 Study to Assess the Efficacy of Lactoferrin for Early Treatment of COVID-19

By |2021-04-07T13:12:18-07:00April 6th, 2021|

About the Study The goal of this study is to examine the effectiveness of lactoferrin, an over-the-counter dietary supplement isolated from bovine milk whey, in treating early COVID-19. Currently, there are few treatment options available for those with COVID-19; lactoferrin potentially represents a commercially available treatment option to those with COVID-19 who are not sick [...]

Covid19 Drug Repurposing @ U-M Center for Drug Repurposing

By |2021-03-18T15:25:40-07:00March 18th, 2021|

The U-M Center for Drug Repurposing has built a drug repurposing platform to address Covid19.  We have developed several human cell-based SARS-CoV-2 infection models and have screened FDA approved drugs, clinical candidates and some dietary supplements. Morphological profiling of SARS-CoV-2 infected Huh7 cells (MOI of 0.2 for 48 hrs). A) Clockwise: Representative field with [...]

Old Drug, New Tricks: Existing Medicines Show Promise in Fighting Cancer

By |2020-01-22T10:14:49-08:00January 22nd, 2020|

Researchers at the Broad Institute, Dana Farber Cancer Institute, MIT and Harvard just published a drug repurposing screen in Nature Cancer of  4,518 compounds, mostly FDA approved drugs and clinical candidates against 578 human cancer cell lines.  The technology that enabled this massively parallel anticancer drug discovery approach is the PRISM bar-coded cell lines [...]

New Repurposed Drug, Brequinar Might Treat Aggressive Lung Cancer

By |2019-11-20T12:34:39-08:00November 20th, 2019|

Despite significant progress, lung cancer remains the nation’s leading cause of cancer related deaths. Recently, the Jacks Lab from MIT has unveiled a new repurposed drug candidate for a form of aggressive lung cancer called small cell lung cancer (SCLC). This exciting result comes from a 5,000 gene CRISPR knock out model in mice [...]

Drug Repurposing, HIV drug used to treat Friedreich’s Ataxia

By |2019-11-05T12:01:59-08:00November 5th, 2019|

Rufini et al. provide an excellent case study of drug repurposing using a known drug, Etravirine, an antiretroviral used to treat human immunodeficiency (HIV)-infected patients. Here Etravirine was used to treat Friedreich’s ataxia (FRDA) an autosomal-recessive disease characterized by gait instability and loss of muscle coordination. Rufini et al. discuss the process of uncovering [...]

Review: Drug Screening for Genetic Diseases

By |2019-11-05T12:02:48-08:00November 5th, 2019|

Arkin et al. at the University of California, San Francisco provide a tremendously insightful look at the process of small-molecule screening as a way to discover new and innovative ways to treat existing genetic diseases.  This review encompasses the entire process of small-molecule screening starting with conceptualization and experimental design to hit validation and [...]

Overview of Tech: Understanding High-Content Image-Based Assays

By |2019-11-05T12:04:22-08:00November 5th, 2019|

Google in collaboration with the Rubin Lab at Harvard provide a fantastic overview into high-content screening as a tool for understanding disease phenotypes. Highlighting the use of machine learning as a resource for identifying patients with spinal muscular atrophy (SMA) and those without. Many of the methods comprehensively discussed in this paper are specifically [...]

2018 Overview of FDA-Approved Drugs

By |2019-10-29T19:31:58-07:00October 29th, 2019|

The National Center for Advancing Translational Sciences (NCATS) has developed Inxight: Drugs A comprehensive portal for drug development information. NCATS Inxight: Drugs contains information on ingredients in medicinal products, including: US APPROVED DRUGS: 2,553 MARKETED DRUGS: 6,161 INVESTIGATIONAL DRUGS: 6,791 ALL SUBSTANCES: 102,012 2018 Overview of FDA Approved Drugs: - Highest ever number of innovative drugs approved in a year. - FDA approves first-ever RNAi therapeutic. [...]

Meta analysis of drug repurposing trials for obstructive sleep apnea

By |2019-08-19T18:00:47-07:00August 19th, 2019|

A meta-analysis of 17 trials for seven drugs (acetazolamide, donepezil, mirtazapine, ondansetron, paroxetine, protriptyline, theophylline) indicated a small effect for acetazolamide (mean difference in AHI -9.6/h [-17.7; -1.4]; p = 0.02). In the network meta-analysis (I2 = 50%) nine drugs (tramazoline, liraglutide, spironolactone/furosemide, acetazolamide, dronabinol, zonisamide, phentermine, spironolactone, and ondansetron/fluoxetine) significantly lowered the AHI compared to placebo.

Go to Top